Welcome, Guest
Username: Password: Remember me
Cytori´s Technology- Celution, IP etc etc
  • Page:
  • 1

TOPIC: Medistem patent application - auto immune disease

Medistem patent application - auto immune disease 29 Jan 2013 05:52 #71

  • rongside
  • rongside's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 377
  • Thank you received: 196
Fas I would like to hear your view on the Medistem patent application for auto immune diseases, and the auto immune market in general.

medisteminc.com/2012/medistem-receives-notice-of-patent-allowance-covering-fat-stem-cell-therapy-of-autoimmune-diseases/

According to the press release they have/claim earliest priority date of December 2006. Given that Cytori(?) has been treating fistula arising from Crohn's which is an autoimmune disease for a very long time, what implications does this have for CYTX in addressing this/these market (s). Given that we already have the French researching Celution for treatment of scleroderma are we at risk? Conditions such as MS, Lupus, psoriasis etc. are huge markets the implications are serious.

Of course the CEO of Medistem said: “However, due to the ease of implementation of our fat stem cell technology, combined with the major burden that autoimmune diseases have on our health care system, we are highly incentivized to explore partnering, co-development and licensing opportunities.” CYTX's patents in the extraction of the SVF will be a huge factor in its favour. Partner, buyout ?????

Are you aware of anything in this area........... I liked the Hardcore article and am looking forward to the update.

Please Log in or Create an account to join the conversation.

Medistem patent application - auto immune disease 29 Jan 2013 11:33 #73

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3290
  • Thank you received: 1110
Uhh- I guess my answer could be a small book on the topic, but we do not want that either I guess. :whistle:
For that reason, I will try to stick to the main points-
First- ADRCs surely work on a SYSTEMIC basis against auto-immune in general. Strong efficacy in rheumatoid Arthritis. lesser against MS and other auto-immune disorders. The patients of the Panama clinic of Neil Riordan are the living proof of that statement.
Riordan was linked to Medistem in the past- now it is Thomas Ichim and a new CEO.
Second- Tigenix the Belgium Company, which merged with Cellerix completed enrollment of their P 2 rheumatoid Arthritis trial and seem very confident, the treatment works. They work hard on many more auto-immune therapies and yes- they use ADRCs, but cultured.
Third- I am convinced ADRCs, culture very well- much better than marrow cells and therefore lose less of their potency. Tigenix I believe will be swallowed by Roche or Novartis some day is my guess and I believe their management is better than the management of another Company I know..
Fourth- Cytori part 1- if you ask them, fistula after Crohn´s will be a wound healing app or maybe anti-inflammatory. That could fly, since it is a localized treatment and not systemic. Same applies to scleroderma, where they started treating patients with the "light-weight" cases, who have skin rashes and stuff- same again localized vs systemic.
Fifth- Cytori part 2- all these type of disorders smell Astellas to me. In that respect- since Astellas has been researching ADRCs for ages too, I do suspect they are on a track (as BIG PHARMA) of cells plus something, which is surely patentable. Makes the MediStem IP no issue, if that is correct- which is very likely.
So- those were my headlines. :)
The following user(s) said Thank You: rongside

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Medistem patent application - auto immune disease 29 Jan 2013 22:37 #74

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2752
  • Thank you received: 199
fas
Regarding Astellas and a potential partnership...CC made a interesting comment in the last call I believe that something was still possible later this year with Astellas but presented his comment as something of a joint venture with Astellas (paraphrasing)...which was different wording from the past .
Now I have been around long enough not to give much credit to CC's words on any subject....but if I am to listen to them, this does seem to be a evelution of the Astellas relationship ?.....and hard to judge if it is for the positive.
Do you remember the above comment and did it strike you as a change in the relationship either for better or worse ?

Personally...as for partnership deal for 2013 I have limited my hopes to another BARDA style deal with another government as a possibility and if something better does come along I would rather it just be a surprise.
The following user(s) said Thank You: Joncon63

Please Log in or Create an account to join the conversation.

Medistem patent application - auto immune disease 01 Feb 2013 04:52 #77

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3290
  • Thank you received: 1110
Hedge-
I listened to the Showcase presentation once again- no mention there really on Astellas in particular. In the last call, there was a summary on the status of the three Japanese partners including Astellas. You can read the summary below- nothing was mentioned on a JV- which does not mean one cannot be established. Personally I ALWAYS prefer it that way. since you can assign dedicated folks to a JV, who are not distracted by other projects and establish clear goals and objectives for the unit with appropriate oversight by senior personnel. Anyway- thats no issue at present as you can read below- B)


Steve (0:28:13), hi, it's Chris Calhoun. So, as you've mentioned and Cytori established multiple partnerships
over the years, two of which – actually three of which are in Japan. We have a partnership with Astellas and that's
essentially a option for a therapeutic indication that they want to co-develop around the world. And while that
option exercise periods kind of timing out here pretty soon, we are actively working with them towards defining
which areas they want to work on and what a larger more formal strategic partnership looks like. And I think
that's going to ultimately end up in a larger more formal partnership based on our current activity dialog with
them. And that's moving forward.
Timing on that's probably, I'd say some time into Q1 or Q2. So, when I talk about some of the late stage stuff that
we're working on the partnership side, I'm not specifically talking about Astellas although they are one of the ones
in the queue that we think is positively moving forward and we expect will get completed.
The Olympus relationship, as you know, they've undergone a significant amount of change over the last year or
two. And they are refocusing their efforts on kind of their core business, which is really around the medical
technology side. And we've been working pretty closely with our counterparts at Olympus to define how we might
or might not fit into that longer-term strategy for them and what would be the best outcome for both of us and
while there is nothing that's finalized yet, we are exploring different paths and some paths include working
together and there are paths that include that we kind of go our separate ways and I think there are advantages to
both ones. So, as soon as we have something more specific there in terms of a final outcome, we're going to share
that, but as of right now, it's kind of status quo and we are working together as we always have, but we're – at the
same time, we're really exploring what does this relationship look like going forward and how might that change.
So, nothing definitive to say about that yet, except that we're really looking at it together.
Green Hospital has been a partner on the banking side in Japan. There is a number of banks that are in the funnel.
I think we are expecting one more this quarter. Some of them – Green Hospital is really behind selling and driving
these bank sales and we are supporting them and they have been a good partner to us and they continue to be a
good partner and nothing has really changed on that front. So, that's the kind of the overview of the Japanese
partnership discussion.
......................................................................................................................................................................................................................................................

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Medistem patent application - auto immune disease 08 Feb 2013 09:14 #128

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3290
  • Thank you received: 1110
John-
Cleaning up my papers- on auto-immune- from 2011.

Abstract
Prolonged life expectancy, life style and environmental changes have caused a changing
disease pattern in developed countries towards an increase of degenerative and autoimmune
diseases. Stem cells have become a promising tool for their treatment by promoting tissue
repair and protection from immune-attack associated damage. Patient-derived autologous
stem cells present a safe option for this treatment since these will not induce immune
rejection and thus multiple treatments are possible without any risk for allogenic sensitization,
which may arise from allogenic stem cell transplantations. Here we report the outcome of
treatments with culture expanded human adipose–derived mesenchymal stem cells
(hAdMSCs) of 10 patients with autoimmune associated tissue damage and exhausted
therapeutic options, including autoimmune hearing loss, multiple sclerosis, polymyotitis,
atopic dermatitis and rheumatoid arthritis. For treatment, we developed a standardized
culture-expansion protocol for hAdMSCs from minimal amounts of fat tissue, providing
sufficient number of cells for repetitive injections. High expansion efficiencies were routinely
achieved from autoimmune patients and from elderly donors without measurable loss in
safety profile, genetic stability, vitality and differentiation potency, migration and homing
characteristics. Although the conclusions that can be drawn from the compassionate use
treatments in terms of therapeutic efficacy are only preliminary, the data provide convincing
evidence for safety and therapeutic properties of systemically administered AdMSC in human
patients with no other treatment options. The authors believe that ex-vivo-expanded
autologous AdMSCs provide a promising alternative for treating autoimmune diseases.
Further clinical studies are needed that take into account the results obtained from case
studies as those presented here.
Keywords: Autologous adipose mesenchymal stem cells, autoimmune diseases, systemic
stem cell infusion

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Medistem patent application - auto immune disease 08 Feb 2013 09:51 #129

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3290
  • Thank you received: 1110
As author of the HARDCORE article on this site, I am very proud that I know the answer on the quest of the scientists who wrote this article here- this will be important going forward- for medicine in general and cell therapy (only with fat of course) in particular- i.e. there is not a single word on ADRCs in the paper, but it explains the importance of Tregitopes and TREGS. make sure to watch the video of Neil Riordan (video of the month, which has been on site for a year lol- :grin: ) MSCs stop the evil cascade of T-cells. Tregs help getting rid of them. :winky:

Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis

The induction of immunologic tolerance is an important clinical goal in autoimmunity. CD4+ regulatory T (Treg) cells, defined
by the expression of the transcription factor forkhead box P3 (FoxP3), play a central role in the control of autoimmune responses. Quantitative and qualitative defects of Tregs have been postulated to contribute to failed immune regulation in multiple sclerosis
(MS) and other autoimmune diseases. This paper highlights the potential uses of T regulatory cell epitopes (Tregitopes), natural
Treg epitopes found to be contained in human immunoglobulins, as immunomodulating agents in MS. Tregitopes expand Treg
cells and induce “adaptive Tregs” resulting in immunosuppression and, therefore, are being considered as a potential therapy
for autoimmune diseases. We will compare Tregitopes versus intravenous immunoglobulin (IVIg) in the treatment of EAE with
emphasis on the potential applications of Tregitope for the treatment of MS.



File Attachment:

File Name: Tregitopes_MS-treatment.pdf
File Size: 2,693 KB
Attachments:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.113 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites